Adam H. Schechter

Chairman, President and Chief Executive Officer
Global business leader Adam Schechter became chief executive officer of Labcorp (NYSE: LH) on Nov. 1, 2019, and chairman on May 13, 2020. Prior to that, Schechter was named lead independent director in January 2019 after serving on the board since April 2013.

A highly respected healthcare executive with a deep understanding of the U.S. and global environments, Schechter joined Labcorp after a long and distinguished career at Merck, where he served as executive vice president and president of global human health, and was a member of the executive committee. At Merck, among other accomplishments, Schechter focused on ensuring that Merck’s medicines and vaccines were available to people around the world; led a large global organization across the spectrum of commercial operations; transformed Merck’s commercial model; and led the integration of Merck and Schering-Plough. Prior to his most recent role from 2010 to 2018 as president of global human health, Merck’s global pharmaceuticals and vaccines business, Schechter served as president of the global pharmaceutical business from 2007 to 2010. Before that, he led Merck’s U.S. pharmaceutical business. He began his career with Merck in 1988 as a sales representative.

Schechter has served as a director and member of the Audit Committee and the Compliance & Quality Committee of the Board of Directors of DaVita, Inc., since September 2022. He is also the board chair for, chair of the Corporate Advisory Council of the National Alliance for Hispanic Health, and executive advisor to the Healthy Americas Foundation.

Schechter holds a Bachelor of Arts in Biology from La Salle University and was awarded an honorary Doctor of Humane Letters degree from the university in 2021. Previously, he served on the boards of the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he led the Policy and Access Committee, the Healthcare Leadership Council and the Merial Animal Health Company.